Drugs / SAL003
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07278830 | Jun 2023 → May 2024 | hyperlipidemia | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07253584 | Dec 2023 → Jun 2025 | hyperlipidemia, combined, 2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT07295418 | Oct 2023 → Apr 2025 | hyperlipidemia | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAL003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07253584 ↗ |
| Modality | Monoclonal antibody | “SAL003, a recombinant fully human anti-PCSK9 monoclonal antibody” NCT07253584 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT07253584 ↗ |
| Target | PCSK9 | “SAL003, a recombinant fully human anti-PCSK9 monoclonal antibody” NCT07253584 ↗ |